CRBU / Caribou Biosciences offers more stock, and shares fall

Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs. more_horizontal

BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharm more_horizontal

Here is how Caribou Biosciences, Inc. (CRBU) and DexCom (DXCM) have performed compared to their sector so far this year. more_horizontal

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compar more_horizontal

It's cumbersome and costly to manufacture complicated cell therapies. Caribou Biosciences and CRISPR Therapeutics have a better way of doing things. more_horizontal

Sudden and dramatic downturns in a company's share price can sometimes represent an incredible buying opportunity. Caribou Biosciences and AT&T may fa more_horizontal

Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 for the treatment of patients with relapsed/ref more_horizontal

Shares of Caribou Biosciences Inc. CRBU, +4.90% tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million shar more_horizontal